Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen a significant increase, with a rise of over 9%, currently trading at 10.35 HKD, with a transaction volume of 201 million HKD. This surge follows the announcement of a substantial share acquisition by the Government of Singapore Investment Corporation (GIC) [1] Group 1: Share Acquisition - On August 18, GIC Private Limited increased its stake in Basestone Pharmaceuticals by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD. This acquisition raised GIC's ownership from 0.00% to 5.49% [1] Group 2: Clinical Trials and Product Pipeline - Guotou Securities reported that Basestone's core product, the second-generation IO product CS2009, is currently undergoing global multi-center Phase I/II clinical trials in Australia and China, with plans to expand to the U.S. for Phase II enrollment. The company expects to exceed 100 patients by the end of the year [1] - The company plans to present data from the Phase I clinical study, including safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity, at the ESMO conference in October 2025, which is highly anticipated [1] - Given the potential for product volume growth and a rich clinical development pipeline, the future development prospects for the company appear promising [1]
基石药业-B再涨超9% GIC斥资超6亿港元增持公司股份 二代IO产品即将披露数据